SUBSCRIBE
SUBSCRIBE

Palleon Pharmaceuticals

NEWS
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Genetown
Palleon Pharma Bursts Onto the Scene With $47.6 Million and a New R&D Approach
October 4, 2017
 · 
2 min read
IN THE PRESS
FDA
Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology
January 20, 2022
 · 
1 min read
Business
Palleon Pharmaceuticals Appoints Denis Patrick to Its Board of Directors
December 16, 2021
 · 
2 min read
Drug Development
Palleon Presents Data on Sialoglycan Degradation Platform That Enhances Anti-Tumor T-Cell Immunity
November 9, 2021
 · 
2 min read
Business
Palleon Pharmaceuticals Appoints David Johnson to Its Board of Directors
November 2, 2021
 · 
2 min read
Drug Development
Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting
October 25, 2021
 · 
3 min read
Business
Palleon Pharmaceuticals Appoints David Feltquate as Chief Medical Officer
June 9, 2021
 · 
3 min read
Genetown
Palleon Pharmaceuticals Presents Data Suggesting Role of Hypersialylation in Metastatic Melanoma Patients’ Resistance to PD1 Inhibitors
April 9, 2021
 · 
3 min read
Business
Palleon Pharmaceuticals Appoints Nikola Trbovic to Its Board of Directors
February 8, 2021
 · 
2 min read
Business
Palleon Pharmaceuticals Appoints Deepa Pakianathan, Ph.D., to its Board of Directors
December 4, 2020
 · 
2 min read
Deals
Palleon Pharmaceuticals Raises $100 million Series B to Develop Drugs Targeting Glycan-Mediated Immune Regulation to Treat Cancer and Inflammatory Diseases
September 17, 2020
 · 
4 min read
Load More
JOBS